litlas
ログインアカウント作成

Michael R. McClung

1977–2025 年に発表

別表記
MICHAEL R. McCLUNG
126
論文数
32,351
被引用数
89
h 指数
124
i10 指数

被引用数

Michael R. McClung の年別被引用数1979 年: 被引用 2 件1981 年: 被引用 3 件1982 年: 被引用 4 件1983 年: 被引用 2 件1984 年: 被引用 4 件1985 年: 被引用 2 件1986 年: 被引用 3 件1987 年: 被引用 1 件1988 年: 被引用 3 件1990 年: 被引用 3 件1992 年: 被引用 6 件1993 年: 被引用 6 件1994 年: 被引用 4 件1995 年: 被引用 18 件1996 年: 被引用 29 件1997 年: 被引用 40 件1998 年: 被引用 34 件1999 年: 被引用 59 件2000 年: 被引用 83 件2001 年: 被引用 76 件2002 年: 被引用 125 件2003 年: 被引用 129 件2004 年: 被引用 127 件2005 年: 被引用 137 件2006 年: 被引用 216 件2007 年: 被引用 173 件2008 年: 被引用 245 件2009 年: 被引用 183 件2010 年: 被引用 249 件2011 年: 被引用 246 件2012 年: 被引用 246 件2013 年: 被引用 194 件2014 年: 被引用 202 件2015 年: 被引用 233 件2016 年: 被引用 223 件2017 年: 被引用 246 件2018 年: 被引用 233 件2019 年: 被引用 658 件2020 年: 被引用 937 件2021 年: 被引用 801 件2022 年: 被引用 703 件2023 年: 被引用 498 件2024 年: 被引用 913 件2025 年: 被引用 476 件2026 年: 被引用 11 件1980 年は被引用が無いため表示していません1989 年は被引用が無いため表示していません1991 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,183 件、この内訳の 22.2%中国: 引用元論文 1,096 件、この内訳の 11.1%イギリス: 引用元論文 768 件、この内訳の 7.8%カナダ: 引用元論文 460 件、この内訳の 4.7%イタリア: 引用元論文 418 件、この内訳の 4.3%オーストラリア: 引用元論文 381 件、この内訳の 3.9%ドイツ: 引用元論文 380 件、この内訳の 3.9%スイス: 引用元論文 324 件、この内訳の 3.3%フランス: 引用元論文 317 件、この内訳の 3.2%ベルギー: 引用元論文 315 件、この内訳の 3.2%日本: 引用元論文 289 件、この内訳の 2.9%オランダ: 引用元論文 258 件、この内訳の 2.6%
0%22.2%その他 26.9%

機関

分野

  • Medicine74.5%
  • Biochemistry, Genetics and Molecular Biology18.4%
  • Engineering1.8%
  • Neuroscience0.9%
  • Nursing0.8%
  • Immunology and Microbiology0.6%
  • その他3%

トピック

  • Bone health and osteoporosis research20%
  • Bone health and treatments11.9%
  • Bone Metabolism and Diseases10.7%
  • Bone and Joint Diseases4.5%
  • Hip and Femur Fractures3.5%
  • Parathyroid Disorders and Treatments2.8%
  • その他46.6%

共著者

全論文

検索で開く
  1. Osteoporosis

    著者: Juliet Compston, Michael R. McClung, William D. Leslie - The Lancet 2019 被引用: 2,284

  2. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update

    著者: Pauline M. Camacho, Steven M. Petak, Neil Binkley, Dima L. Diab, Leslie S. Eldeiry, Azeez Farooki, Steven T. Harris, Daniel L. Hurley, Jenny Kelly, E. Michael Lewiecki, Rachel Pessah‐Pollack, Michael R. McClung, Sunil J. Wimalawansa, Nelson B. Watts - Endocrine Practice 2020 被引用: 1,109

  3. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

    著者: Steven R. Cummings, Javier San Martín, Michael R. McClung, Ethel S. Siris, Richard Eastell, Ian R. Reid, Pierre Delmas, Holly Brenza Zoog, Matt Austin, Andrea Wang, Štěpán Kutílek, Silvano Adami, José Zanchetta, Cesar Libanati, Suresh Siddhanti, Claus Christiansen - New England Journal of Medicine 2009 被引用: 3,442

  4. Romosozumab in Postmenopausal Women with Low Bone Mineral Density

    著者: Michael R. McClung, Andreas Grauer, Steven Boonen, Michael A. Bolognese, Jacques P. Brown, Adolfo Díez‐Pérez, Bente Langdahl, Jean‐Yves Reginster, José Zanchetta, Scott M. Wasserman, Leonid Katz, Judy Maddox, Yuching Yang, Cesar Libanati, Henry G. Bone - New England Journal of Medicine 2014 被引用: 1,235

  5. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

    著者: Steven R. Cummings, Serge Ferrari, Richard Eastell, Nigel Gilchrist, Jens‐Erik Beck Jensen, Michael R. McClung, Christian Roux, Ove Törring, Ivo Valter, Andrea T Wang, Jacques P. Brown - Journal of Bone and Mineral Research 2017 被引用: 709

  6. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

    著者: for the IOF-IFCC Bone Marker Standards Working Group, Samuel D Vasikaran, Richard Eastell, Olivier Bruyère, A. Joseph Foldes, Patrick Garnero, Andrea Griesmacher, Michael R. McClung, Howard A. Morris, Stuart L. Silverman, Tommaso Trenti, D. A. Wahl, Cyrus Cooper, J. A. Kanis - Osteoporosis International 2010 被引用: 1,172

  7. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

    著者: Michael R. McClung, Jacques P. Brown, Adolfo Díez‐Pérez, Heinrich Resch, John Caminis, Paul Meisner, Michael A. Bolognese, Stefan Goemaere, Henry G. Bone, José Zanchetta, Judy Maddox, Sarah Bray, Andreas Grauer - Journal of Bone and Mineral Research 2018 被引用: 231

  8. Denosumab in Postmenopausal Women with Low Bone Mineral Density

    著者: Michael R. McClung, E. Michael Lewiecki, Stanley Cohen, Michael A. Bolognese, Grattan C. Woodson, Alfred H. Moffett, Munro Peacock, Paul D. Miller, Samuel Lederman, Charles H. Chesnut, Douglas Lain, Alan Kivitz, Donna Holloway, Charlie Zhang, Mark Peterson, Pirow Bekker - New England Journal of Medicine 2006 被引用: 1,215

  9. Skeletal responses to romosozumab after 12 months of denosumab

    著者: Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary Oates - JBMR Plus 2021 被引用: 73

  10. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update Executive Summary

    著者: Pauline M. Camacho, Steven M. Petak, Neil Binkley, Dima L. Diab, Leslie S. Eldeiry, Azeez Farooki, Steven T. Harris, Daniel L. Hurley, Jenny Kelly, E. Michael Lewiecki, Rachel Pessah‐Pollack, Michael R. McClung, Sunil J. Wimalawansa, Nelson B. Watts - Endocrine Practice 2020 被引用: 202

  11. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

    著者: Richard Eastell, Claus Christiansen, Andreas Grauer, Štěpán Kutílek, Cesar Libanati, Michael R. McClung, Ian R. Reid, Heinrich Resch, Ethel S. Siris, Daniel Uebelhart, Andrea Wang, G. Weryha, Steve Cummings - Journal of Bone and Mineral Research 2010 被引用: 247

  12. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    著者: Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos, Henry G. Bone, Bente Langdahl, Kenneth G. Saag, Ian R. Reid, Douglas P. Kiel, Ilaria Cavallari, Marc P. Bonaca, Stephen D. Wiviott, Tobias De Villiers, Ling Xu, Kurt Lippuner, Toshitaka Nakamura, Jean‐Yves Reginster, Jose Adolfo Rodriguez-Portales, C. Roux, José Zanchetta, Cristiano A. F. Zerbini, Jeong‐Gun Park, KyungAh Im, Abby Cange, Laura T. Grip, Norman Heyden, Carolyn DaSilva, Dosinda Cohn, Rachid Massaad, Boyd B. Scott, Nadia Verbruggen, Deborah M. Gurner, Deborah L. Miller, Micki L Blair, Adam B. Polis, S. Aubrey Stoch, Arthur C. Santora, Antonio Lombardi, Albert Leung, Keith D. Kaufman, Marc S. Sabatine, C. Mautalén, Z. Man, José Zanchetta, C. Magaril, Philip N. Sambrook, Jean‐Yves Reginster, Piet Geusens, Stefan Goemaere, Ben Hur Albergaria, Cristiano A. F. Zerbini, Marise Lazaretti Castro, Luiz Henrique de Gregório, Румен Стоилов, Anna-Maria I Borissova, Kiril Hristov Hristozov, Nataliya Temelkova, Ivona Daskalova, Stefka I Kuzmanova, Daniela Yaneva-Bichovska, Anastas Batalov, Pablo Riedemann, José Adolfo Rodríguez Portales, Hai Tang, Han-min Zhu, Zhenlin Zhang, Aijun Chao, Yali Hu, Zhiming Liu, Ju-ming Lu, Ming-cai Qiu, Xin Gao, Shaofen Zhang, Ling Xu, Weibo Xia, Eryuan Liao, Wenying Yang, Wen Wu, Kerong Dai, Renming Hu, Hai Tang, Juan José Jaller, Francisco Cabal, José Fernando Molina, Carlos Curé, Hernan Yupanqui-Lozno, Philippe Chalem, John Londoño, Maurício Abello, Edgardo D Tobias, William Otero, Tatjana Nikolić, Blazenka Miskic, J Štěpán, Václav Vyskočil, Libor Novosád, Jan Slesinger, Pavel Novosad, Erika Vlckova, Ladislav Bortlík, Eva Dokoupilová ほか 313 名 - The Lancet Diabetes & Endocrinology 2019 被引用: 169

  13. Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis

    著者: Andrea Singer, Michael R. McClung, Oth Tran, C. D. Morrow, Shulamit Goldstein, Risa Kagan, Michele McDermott, Alon Yehoshua - Archives of Osteoporosis 2023 被引用: 58

  14. Effects of denosumab on fracture and bone mineral density by level of kidney function

    著者: Sophie A. Jamal, Östen Ljunggren, Catherine Stehman‐Breen, Steven R. Cummings, Michael R. McClung, Stefan Goemaere, Peter R. Ebeling, Edward Franek, YuChing Yang, Ogo Egbuna, Steven Boonen, Paul D. Miller - Journal of Bone and Mineral Research 2011 被引用: 352

  15. Effect of Risedronate on the Risk of Hip Fracture in Elderly Women

    著者: Michael R. McClung, Piet Geusens, Paul D. Miller, H Zippel, W. Bensen, Christian Roux, Silvano Adami, Ignac Fogelman, Terrence Diamond, Richard Eastell, Pierre J. Meunier, Richard D. Wasnich, Maria Greenwald, Jean‐Marc Kaufman, Charles H. Chesnut, Jean‐Yves Reginster - New England Journal of Medicine 2001 被引用: 1,926

  16. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years

    著者: Nelson B. Watts, John T. Grbic, Neil Binkley, Socrates E. Papapoulos, Peter Butler, Xiang Yin, Antoniette Tierney, Rachel B. Wagman, Michael R. McClung - The Journal of Clinical Endocrinology & Metabolism 2019 被引用: 99

  17. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

    著者: Michael R. McClung, Steven T. Harris, Paul D. Miller, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, David L. Kendler, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2012 被引用: 453

  18. Observations following discontinuation of long-term denosumab therapy

    著者: Michael R. McClung, R.B. Wagman, Paul D. Miller, A. Wang, E. Michael Lewiecki - Osteoporosis International 2017 被引用: 220

  19. Hormones and Aging: An Endocrine Society Scientific Statement

    著者: Anne Rentoumis Cappola, Richard J. Auchus, Ghada El‐Hajj Fuleihan, David J. Handelsman, Rita R. Kalyani, Michael R. McClung, Cynthia A. Stuenkel, Michael O. Thorner, Joseph G. Verbalis - The Journal of Clinical Endocrinology & Metabolism 2023 被引用: 82

  20. Vertebral Fractures: Clinical Importance and Management

    著者: David L. Kendler, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, S. T. Harris, Michael R. McClung, Paul D. Miller, John T. Schousboe, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2015 被引用: 315

  21. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use

    著者: Anthony B. Hodsman, Douglas C. Bauer, David W. Dempster, Larry Dian, David A. Hanley, Steven T. Harris, David L. Kendler, Michael R. McClung, Paul D. Miller, Wojciech P. Olszynski, Eric Orwoll, Chui Kin Yuen - Endocrine Reviews 2005 被引用: 721

  22. Bone Mineral Density After Transitioning From Denosumab to Alendronate

    著者: David L. Kendler, Arkadi Chines, Patricia Clark, Peter R. Ebeling, Michael R. McClung, Yumie Rhee, Shuang Huang, Robert Stad - The Journal of Clinical Endocrinology & Metabolism 2019 被引用: 113

  23. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

    著者: Michael R. McClung, MA Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente Langdahl, Judy Maddox, Yifei Shi, Maria Rojeski, Paul Meisner, Andreas Grauer - Osteoporosis International 2020 被引用: 49

  24. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

    著者: Paul D. Miller, Michael A. Bolognese, E. Michael Lewiecki, Michael R. McClung, Beiying Ding, Matthew Austin, Yu Liu, Javier San Martín - Bone 2008 被引用: 574